Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 18/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1506025 | 0.80 | NOTUM (0.51) | NOTUMKDM4EALDH1A1GLAHSD17B10 | |
| SCHEMBL24609209 | 0.80 | NOTUM (0.65) | NOTUMKDM4EALDH1A1GLAHSD17B10 | |
| SCHEMBL24589203 | 0.77 | NOTUM (0.52) | NOTUMKDM4EALDH1A1GLAHSD17B10 | |
| SCHEMBL8270247 | 0.77 | NOTUM (1.00) | NOTUM | |
| SCHEMBL12896228 | 0.76 | NOTUM (0.66) | NOTUMKDM4EALDH1A1GLAHSD17B10 | |
| SCHEMBL2898202 | 0.75 | NOTUM (1.00) | NOTUM | |
| SCHEMBL6127961 | 0.71 | NOTUM (1.00) | NOTUM | |
| SCHEMBL30936946 | 0.71 | ALDH1A1 (0.66) | NOTUMALDH1A1HSD17B10 | |
| SCHEMBL31028720 | 0.71 | NOTUM (0.74) | NOTUM | |
| SCHEMBL24599021 | 0.70 | NOTUM (0.65) | NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022140456-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS | MEKANISTIC THERAPEUTICS LLC (US) | 2022-06-30 | — | — | WO | disclosed |
| US-20170360788-A1 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2017-12-21 | — | — | US | disclosed |
| WO-2016100347-A2 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360788-A1 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | EGFR, ERBB2, ERBB3 | NOTUM 2800/4885KDM4E 2937/4885ALDH1A1 4653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.